Skip to main content
Sean McBride, MD, Radiation Oncology, New York, NY

SeanMatthewMcBrideMDMPH

Radiation Oncology • New York, NY

Head & Neck, Urologic Cancer

Chief, Manhattan Service, Department of Radiation Oncology Associate Attending, Memorial Sloan Kettering Cancer Center

Request Appointment

Overview of Dr. McBride

Dr. Sean McBride is a radiation oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from Yale School of Medicine and has been in practice 9 years. He is one of 106 doctors at Memorial Sloan Kettering Cancer Center and one of 26 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Radiation Oncology. He has more than 70 publications and over 500 citings.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical School
    Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Radiation Oncology, 2009 - 2013
  • Harvard School of Public Health
    Harvard School of Public HealthMPH, 2011 - 2012
  • California Pacific Medical Center
    California Pacific Medical CenterInternship, Internal Medicine, 2008 - 2009
  • Yale School of Medicine
    Yale School of MedicineClass of 2008

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2023 - Present
  • NY State Medical License
    NY State Medical License 2013 - 2026
  • NJ State Medical License
    NJ State Medical License 2015 - 2025
  • MA State Medical License
    MA State Medical License 2011 - 2014
  • American Board of Radiology Radiation Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Biomarker predictors of outcome from a randomized trial of nivolumab +/- stereotactic body radiotherapy (SBRT) in metastatic (M1) head and neck squamous cell carcinoma... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Baseline genomic and circulating tumor cell (CTC) correlative data from very high-risk (VHR), localized, node-negative prostate cancer patients. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Apalutamide + abiraterone + leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer (PCa). 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Join now to see all

Press Mentions

  • New MSK Radiation Approach Means Fewer Side Effects for More Patients with HPV-Related Head and Neck Cancer
    New MSK Radiation Approach Means Fewer Side Effects for More Patients with HPV-Related Head and Neck CancerJanuary 20th, 2022
  • ‘Contrary’ to Wide Belief, Abscopal Effect Is Rare in Cancer
    ‘Contrary’ to Wide Belief, Abscopal Effect Is Rare in CancerJanuary 7th, 2021
  • New SU2C Teams Accelerate Clinical Trials for Difficult Breast & Prostate Cancers
    New SU2C Teams Accelerate Clinical Trials for Difficult Breast & Prostate CancersSeptember 16th, 2019
  • Join now to see all

Dr. Sean McBride, Dr. Sean McBride, MD, Dr. S McBride, Dr. Sean Matthew McBride